Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms

References

• Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol. Blood Marrow Transplant.13(Suppl. 1), 64–72 (2007).
   PubMed Web of Science ®Google Scholar
• Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. In: Hematology 2007: American Society of Hematology Education Program Book. Gewirtz AM, Winter JN, Zuckerman K (Eds). American Society of Hematology, Washington, DC, USA 240–245 (2006).
   Google Scholar
• WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH (Ed.). WHO, Lyon, France (2008).
   Google Scholar
• Appelbaum FR, Clift R, Radich J, Anasetti C, Buckner CD. Bone marrow transplantation for chronic myelogenous leukemia. Semin. Oncol.22, 405–411 (1995).
   PubMed Web of Science ®Google Scholar
• Maziarz RT. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? Curr. Opin. Hematol.15, 127–133 (2008).
   PubMed Web of Science ®Google Scholar
• Zhan H, Spivak JL. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin. Adv. Hematol. Oncol.7, 334–342 (2009).
   PubMedGoogle Scholar
• Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med.352, 1779–1790 (2005).
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell7, 387–397 (2005).
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet365, 1054–1061 (2005).
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature434, 1144–1148 (2005).
   PubMed Web of Science ®Google Scholar
• Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer7, 673–683 (2007).
   PubMed Web of Science ®Google Scholar
• Scott B, Deeg HJ. Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract. Res. Clin. Haematol. J.19, 519–522 (2006).
   PubMed Web of Science ®Google Scholar
• Pardanani A, Hood J, Lasho T et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia21, 1658–1668 (2007).
   PubMed Web of Science ®Google Scholar
• Goh KC, Ong WC, Hu C et al. SB1518: a potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders. Blood110, 165A–166A, 538 (2007).
   Google Scholar
• Mesa RA, Verstovsek S, Kantarjian HM et al. INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and frank cachexia in patients with myelofibrosis (MF). Blood112(11), 621–622 (2008).
   Google Scholar
• Moliterno AR, Roboz GJ, Carroll M, Luger S, Hexner E, Bensen-Kennedy DM. An open-label study of CEP-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. Blood112(11), 44 (2008).
   Google Scholar
• Paquette R, Sokol L, Shah NP et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood112(11), 971 (2008).
   Google Scholar
• Pardanani AD, Gotlib J, Jamieson C et al. A Phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. Blood112(11), 43–44 (2008).
   Google Scholar
• Verstovsek S, Kantarjian HM, Pardanani AD et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myleofibrosis (Post PV/ETMF). Blood112(11), 1762 (2008).
   Web of Science ®Google Scholar
• Verstovsek S, Pardanani AD, Shah NP. et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood112(11), 206–207 (2008).
   Google Scholar
• Scott BL, Sandmaier BM. Outcomes with myeloid malignancies. In: Hematology 2006: American Society of Hematology Education Program Book. Berliner N, Linker C, Schiffer CA (Eds). American Society of Hematology, Washington, DC, USA 381–389 (2006).
   Google Scholar
• Baron F, Storb R. Current roles for allogeneic hematopoietic cell transplantation following non-myeloablative or reduced-intensity conditioning. Clin. Adv. Hematol. Oncol.3, 799–813 (2005).
   PubMedGoogle Scholar
• Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia20, 1661–1672 (2006).
   PubMed Web of Science ®Google Scholar
• Finke J, Nagler A. Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning – is there still an upper age limit? A focus on myeloid neoplasia. Leukemia21, 1357–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Mackinnon S, Childs RW. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol. Blood Marrow Transplant.13(Suppl. 1), 87–97 (2007).
   PubMed Web of Science ®Google Scholar
• Antin JH. Reduced-Intensity Stem Cell Transplantation: “…whereof a little more than a little is by much too much”. King Henry IV, part 1, I, 2. In: Hematology 2007: American Society of Hematology Education Program Book. Gewirtz AM, Winter JN, Zuckerman K (Eds). American Society of Hematology, Washington, DC, USA 47–54 (2007).
   Google Scholar
• Alousi A, de Lima M. Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Clin. Adv. Hematol. Oncol.5, 560–570 (2007).
   PubMedGoogle Scholar
• Storb R. Reduced-intensity conditioning transplantation in myeloid malignancies. Curr. Opin. Oncol.21(Suppl. 1), S3–S5 (2009).
   PubMedGoogle Scholar
• Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. In: Hematology 2001: American Society of Hematology Education Program Book. Schechter GP, Broudy VC, Williams ME (Eds). The American Society of Hematology, Washington, DC, USA 375–391 (2001).
   Google Scholar
• Baron F, Storb R. The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. Best Pract. Res. Clin. Haematol. J.19, 637–653 (2006).
   PubMed Web of Science ®Google Scholar
• Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med.300, 1068–1073 (1979).
   PubMed Web of Science ®Google Scholar
• Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED; the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med.304, 1529–1533 (1981).
   PubMed Web of Science ®Google Scholar
• Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant. Proc.13, 248–251 (1981).
   PubMed Web of Science ®Google Scholar
• Martin PJ, Hansen JA, Buckner CD et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood66, 664–672 (1985).
   PubMed Web of Science ®Google Scholar
• Maraninchi D, Gluckman E, Blaise D et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet2, 175–178 (1987).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Mittermüller J, Clemm Ch et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood76, 2462–2465 (1990).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood86, 2041–2050 (1995).
   PubMed Web of Science ®Google Scholar
• Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood76, 1867–1871 (1990).
   PubMed Web of Science ®Google Scholar
• Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood77, 1660–1665 (1991).
   PubMed Web of Science ®Google Scholar
• Baron F, Maris MB, Sandmaier BM et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning. J. Clin. Oncol.23, 1993–2003 (2005).
   PubMed Web of Science ®Google Scholar
• Kahl C, Storer BE, Sandmaier BM et al. Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after non-myeloablative conditioning. Blood110, 2744–2748 (2007).
   PubMed Web of Science ®Google Scholar
• Giralt S, Ballen K, Rizzo D et al. Reduced‑intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol. Blood Marrow Transplant.15, 367–369 (2009).
   PubMed Web of Science ®Google Scholar
• Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood89, 3048–3054 (1997).
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood97, 3390–3400 (2001).
   PubMed Web of Science ®Google Scholar
• Giralt S, Logan B, Rizzo D et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the National Marrow Donor Program. Biol. Blood Marrow Transplant.13, 844–852 (2007).
   PubMed Web of Science ®Google Scholar
• Radich JP. The biology of CML blast crisis. In: Hematology 2007: American Society of Hematology Education Program Book. Gewirtz AM, Winter JN, Zuckerman K (Eds). American Society of Hematology, Washington, DC, USA 384–391 (2007).
   Google Scholar
• Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood109, 3207–3213 (2007).
   PubMed Web of Science ®Google Scholar
• Radich JP, Olavarria E, Apperley JF. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol. Oncol. Clin. North Am. J.18, 685–702 (2004).
   PubMed Web of Science ®Google Scholar
• Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood101, 441–445 (2003).
   PubMed Web of Science ®Google Scholar
• Crawley C, Lalancette M, Szydlo R et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood105, 4532–4539 (2005).
   PubMed Web of Science ®Google Scholar
• Weisser M, Schleuning M, Ledderose G et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant.34, 1083–1088 (2004).
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic Phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant.36, 1043–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Kerbauy FR, Storb R, Hegenbart U et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia19, 990–997 (2005).
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Detry MA, Giralt S et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood110, 3456–3462 (2007).
   PubMed Web of Science ®Google Scholar
• Lange T, Deininger M, Brand R et al.BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia18, 1468–1475 (2004).
   PubMed Web of Science ®Google Scholar
• Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringden O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after non-myeloablative conditioning and allogeneic stem cell transplantation. Blood101, 469–472 (2003).
   PubMed Web of Science ®Google Scholar
• Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood88, 1013–1018 (1996).
   PubMed Web of Science ®Google Scholar
• Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer106, 623–630 (2006).
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood113, 2895–2901 (2009).
   PubMed Web of Science ®Google Scholar
• Papageorgiou SG, Castleton A, Bloor A, Kottaridis PD. Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant.38, 721–727 (2006).
   PubMed Web of Science ®Google Scholar
• Kerbauy DMB, Gooley TA, Sale GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol. Blood Marrow Transplant.13, 355–365 (2007).
   PubMed Web of Science ®Google Scholar
• Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood99, 2255–2258 (2002).
   PubMed Web of Science ®Google Scholar
• Kröger N, Holler E, Kobbe G et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood DOI:10.1182/blood-2009–2007–234880 (2009) (Epub ahead of print).
   Google Scholar
• Rondelli D, Barosi G, Bacigalupo A et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood105, 4115–4119 (2005).
   PubMed Web of Science ®Google Scholar
• Merup M, Lazarevic V, Nahi H et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br. J. Haematol.135, 367–373 (2006).
   PubMed Web of Science ®Google Scholar
• Snyder DS, Palmer J, Stein AS et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol. Blood Marrow Transplant.12, 1161–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Laport GG, Sandmaier BM, Storer BE et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol. Blood Marrow Transplant.14, 246–255 (2008).
   PubMed Web of Science ®Google Scholar
• Kroger N, Thiele J, Zander A et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp. Hematol.35, 1719–1722 (2007).
   PubMed Web of Science ®Google Scholar
• Barosi G, Ambrosetti A, Centra A et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood91, 3630–3636 (1998).
   PubMed Web of Science ®Google Scholar
• Guardiola P, Anderson JE, Bandini G et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood93, 2831–2838 (1999).
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Sadegi B, Wilbur A et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br. J. Haematol.141, 80–83 (2008).
   PubMed Web of Science ®Google Scholar
• Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood89, 3055–3060 (1997).
   PubMed Web of Science ®Google Scholar
• Kashyap A, Wingard J, Cagnoni P et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol. Blood. Marrow. Transplant.8, 493–500 (2002).
   PubMed Web of Science ®Google Scholar
• Bacher U, Klyuchnikov E, Wiedemann B, Kroeger N, Zander AR. Safety of conditioning agents for allogeneic haematopoietic transplantation. Expert Opin. Drug Saf.8, 305–315 (2009).
   PubMed Web of Science ®Google Scholar
• Cutting R, Mirelman A, Vora A. Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation. Br. J. Haematol.143, 748–751 (2008).
   PubMed Web of Science ®Google Scholar
• Kroger N, Shimoni A, Zabelina T et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant.37, 339–344 (2006).
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk. Lymphoma48, 2352–2359 (2007).
   PubMed Web of Science ®Google Scholar
• McDonald GB, Slattery JT, Bouvier ME et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood101, 2043–2048 (2003).
   PubMed Web of Science ®Google Scholar
• Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans (editorial). Bone Marrow Transplant.25, 345–350 (2000).
   PubMed Web of Science ®Google Scholar
• Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica85, 304–313 (2000).
   PubMed Web of Science ®Google Scholar
• Champlin R, Khouri I, Kornblau S et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol. Oncol. Clin. North Am. J.13, 1041–1057 (1999).
   PubMed Web of Science ®Google Scholar
• Pagel JM, Gooley TA, Rajendran J et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood DOI:10.1182/blood-2009–2003–213298 (2009) (Epub ahead of print).
   Google Scholar
• de Lima M, Champlin RE, Thall PF et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia22, 258–264 (2008).
   PubMed Web of Science ®Google Scholar
• Green DJ, Pagel JM, Nemecek ER et al. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood114, 1226–1235 (2009).
   PubMed Web of Science ®Google Scholar
• Nakamae H, Wilbur DS, Hamlin DK et al. Biodistribution, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the a-emitting radionuclides bismuth-213 or astatine-211. Cancer Res.69, 2408–2415 (2009).
   PubMed Web of Science ®Google Scholar
• Pagel JM. Radioimmunotherapeutic approaches for leukemia: the past, present and future. Cytotherapy10, 13–20 (2008).
   PubMed Web of Science ®Google Scholar
• Walter RB, Boyle KM, Appelbaum FR, Bernstein ID, Pagel JM. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Blood111, 4813–4816 (2008).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood100, 1590–1595 (2002).
   PubMed Web of Science ®Google Scholar
• Olavarria E, Ottmann OG, Deininger M et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia17, 1707–1712 (2003).
   PubMed Web of Science ®Google Scholar
• Hess G, Bunjes D, Siegert W et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective Phase II open-label multicenter study. J. Clin. Oncol.23, 7583–7593 (2005).
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Snyder DS, Flowers MED et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood109, 2791–2793 (2007).
   PubMed Web of Science ®Google Scholar
• Olavarria E, Siddique S, Griffiths MJ et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood110, 4614–4617 (2007).
   PubMed Web of Science ®Google Scholar
• Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant.42, 757–760 (2008).
   PubMed Web of Science ®Google Scholar
• Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood109, 500–502 (2007).
   PubMed Web of Science ®Google Scholar
• Shah NP, Olszynski P, Sokol L et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood112(11), 44 (2008).
   Google Scholar
• Martino R, Caballero MD, Simón JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood100, 2243–2245 (2002).
   PubMed Web of Science ®Google Scholar
• Kroger N, Perez-Simon JA, Myint H et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol. Blood Marrow Transplant.10, 698–708 (2004).
   PubMed Web of Science ®Google Scholar
• Blaise DP, Boiron JM, Faucher C et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer104, 1931–1938 (2005).
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Le Blanc K. Prophylaxis of acute GVHD: manipulate the graft or the environment? Baillieres Best Pract. Res. Clin. Haematol.21, 165–176 (2008).
   Web of Science ®Google Scholar
• Ho VT. Graft manipulation: T cell depletion and tumor cell purging. In: Hematopoietic Stem Cell Transplantation. Soiffer RJ (Ed.). Human Press, NJ, USA 653–686 (2008).
   Google Scholar
• Mohty M, Bay JO, Faucher C et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood102, 470–476 (2003).
   PubMed Web of Science ®Google Scholar
• Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann. Intern. Med.108, 806–814 (1988).
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after non-myeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood99, 4357–4363 (2002).
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Turnbull BB, Heydari K et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood114, 1099–1109 (2009).
   PubMed Web of Science ®Google Scholar
• Lan F, Zeng D, Higuchi M, Huie P, Higgins JP, Strober S. Predominance of NK1.1+TCR αβ+ or DX5+TCR αβ+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: “natural suppressor” cells. J. Immunol.167, 2087–2096 (2001).
   PubMed Web of Science ®Google Scholar
• Armand P, Gannamaneni S, Kim HT et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J. Clin. Oncol.26, 5767–5774 (2008).
   PubMed Web of Science ®Google Scholar
• Valmori D, Tosello V, Souleimanian NE et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J. Immunol.177, 944–949 (2006).
   PubMed Web of Science ®Google Scholar
• Sun K, Welniak LA, Panoskaltsis-Mortari A et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl Acad. Sci.101, 8120–8125 (2004).
   PubMed Web of Science ®Google Scholar
• Reddy P, Maeda Y, Hotary K et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA101, 3921–3926 (2004).
   PubMed Web of Science ®Google Scholar
• Krijanovski OI, Hill GR, Cooke KR et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood94, 825–831 (1999).
   PubMed Web of Science ®Google Scholar
• Blazar BR, Weisdorf DJ, DeFor T et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood108, 3216–3222 (2006).
   PubMed Web of Science ®Google Scholar
• Koreth J, Stevenson KE, Kim HT et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood114, 3956–3959 (2009).
   PubMed Web of Science ®Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol.8, 726–736 (2008).
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet363, 1439–1441 (2004).
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood106, 2912–2919 (2005).
   PubMed Web of Science ®Google Scholar
• Sorror ML, Sandmaier BM, Storer BE et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J. Clin. Oncol.25, 4246–4254 (2007).
   PubMed Web of Science ®Google Scholar